妇产科指南

订阅

MedSci主页 / 所有栏目 / 妇产科指南

英国联合共识指南: 生殖系癌症易感基因变异的单基因疾病的产前和植入前基因检测

2023-06-19 英国遗传医学会癌症遗传学小组和胎儿基因组小组 BJOG . 2023 Jun 19 发表于安徽省

无创产前基因测序无创产前基因检测生殖系癌症

英国遗传医学会癌症遗传学小组和胎儿基因组小组发布联合共识：生殖系癌症易感基因变异的单基因遗传病的产前检测指南。癌症易感基因的种系致病变异检测现在是一种常见和常规的做法，以指导癌症患者的管理，并为那些遗

中文标题：

英国联合共识指南: 生殖系癌症易感基因变异的单基因疾病的产前和植入前基因检测

英文标题：

Prenatal and pre-implantation genetic testing for monogenic disorders for germline cancer susceptibility gene variants: UK joint consensus guidance

发布机构：

英国遗传医学会癌症遗传学小组和胎儿基因组小组

发布日期：

2023-06-19

简要介绍：

英国遗传医学会癌症遗传学小组和胎儿基因组小组发布联合共识：生殖系癌症易感基因变异的单基因遗传病的产前检测指南。癌症易感基因的种系致病变异检测现在是一种常见和常规的做法，以指导癌症患者的管理，并为那些遗传风险增加的人确定监测和降低风险的选择。对于少数与生殖系癌症易感基因变异相关的疾病，癌症风险是确定的，关于单基因疾病植入前基因测试(PGT-M)和这些变异的产前诊断测试选项的受孕前讨论得到了医疗保健专业人员、法律机构和公众的支持。

相关资料下载：
BJOG - 2023 - Wafik - Prenatal and pre‐implantation genetic testing for monogenic disorders for germline cancer.pdf
评论区 (4)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=2145166, encodeId=21c4214516636, content=学习了 打卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Jun 28 09:23:06 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144977, encodeId=d73b21449e726, content=打卡谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Tue Jun 27 09:25:42 CST 2023, time=2023-06-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144757, encodeId=cf192144e5720, content=打卡学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Mon Jun 26 09:12:21 CST 2023, time=2023-06-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144034, encodeId=b3af214403499, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Wed Jun 21 08:24:13 CST 2023, time=2023-06-21, status=1, ipAttribution=辽宁省)]
    2023-06-28 智慧药 来自上海

    学习了 打卡

    0

  2. [GetPortalCommentsPageByObjectIdResponse(id=2145166, encodeId=21c4214516636, content=学习了 打卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Jun 28 09:23:06 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144977, encodeId=d73b21449e726, content=打卡谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Tue Jun 27 09:25:42 CST 2023, time=2023-06-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144757, encodeId=cf192144e5720, content=打卡学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Mon Jun 26 09:12:21 CST 2023, time=2023-06-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144034, encodeId=b3af214403499, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Wed Jun 21 08:24:13 CST 2023, time=2023-06-21, status=1, ipAttribution=辽宁省)]
    2023-06-27 智慧药 来自上海

    打卡谢谢

    0

  3. [GetPortalCommentsPageByObjectIdResponse(id=2145166, encodeId=21c4214516636, content=学习了 打卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Jun 28 09:23:06 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144977, encodeId=d73b21449e726, content=打卡谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Tue Jun 27 09:25:42 CST 2023, time=2023-06-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144757, encodeId=cf192144e5720, content=打卡学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Mon Jun 26 09:12:21 CST 2023, time=2023-06-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144034, encodeId=b3af214403499, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Wed Jun 21 08:24:13 CST 2023, time=2023-06-21, status=1, ipAttribution=辽宁省)]
    2023-06-26 智慧药 来自上海

    打卡学习了

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=2145166, encodeId=21c4214516636, content=学习了 打卡, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Wed Jun 28 09:23:06 CST 2023, time=2023-06-28, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144977, encodeId=d73b21449e726, content=打卡谢谢, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Tue Jun 27 09:25:42 CST 2023, time=2023-06-27, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144757, encodeId=cf192144e5720, content=打卡学习了, beContent=null, objectType=guider, channel=null, level=null, likeNumber=30, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210901/969603a2377544169c0528539edd5ab7/50bbe992202d43569f6cc40d89829e36.jpg, createdBy=b54c5537441, createdName=智慧药, createdTime=Mon Jun 26 09:12:21 CST 2023, time=2023-06-26, status=1, ipAttribution=上海), GetPortalCommentsPageByObjectIdResponse(id=2144034, encodeId=b3af214403499, content=学习, beContent=null, objectType=guider, channel=null, level=null, likeNumber=33, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=e2716443372, createdName=ms300, createdTime=Wed Jun 21 08:24:13 CST 2023, time=2023-06-21, status=1, ipAttribution=辽宁省)]
    2023-06-21 ms300 来自辽宁省

    学习

    0

拓展阅读

Cancer Res：研究人员确认恶性生殖细胞肿瘤分子开关

最近，英国剑桥大学研究人员称，一种名为LIN28的蛋白在恶性生殖细胞肿瘤的形成过程中起着重要作用，是促发癌症的关键“开关”。这一发现对于开发新的恶性生殖细胞肿瘤治疗方法具有重要意义。 恶性生殖细胞肿瘤是一种各个年龄段男女都可能罹患的癌症，如睾丸癌、卵巢癌皆属于此列。虽然目前的化疗疗法可在一定程度上治疗该类疾病，但化疗产生的副作用也很严重，会损害患者的听力，造成肾脏、肺